Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Factsheet describing the long-term follow-up of the ASPEN trial -zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.
ASPEN is an open-label, randomized, Phase 3 study comparing the safety, efficacy and clinical benefit of zanubrutinib
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.
The satellite symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.